Johnson & Johnson $JNJ Stock Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the third quarter, Holdings Channel reports. The fund owned 123,213 shares of the company’s stock after selling 4,024 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $32,619,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co lifted its position in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $43,000. Polaris Financial Partners purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth $56,000. Finally, Bullseye Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $63,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. Scotiabank restated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Evercore set a $300.00 price objective on Johnson & Johnson in a research note on Tuesday. Finally, Guggenheim reissued a “buy” rating and set a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson raised its 2026 outlook, calling for approximately $101.2 billion in sales at the midpoint and adjusted earnings per share of $11.05–$11.15. Its latest quarter also modestly exceeded expectations, with adjusted EPS of $2.59 versus the $2.53 consensus and revenue of $25.40 billion. Johnson & Johnson Drugs Lift Guidance, but Is 23 Times Earnings Fair?
• Positive Sentiment: The company extended its dividend-growth streak to 64 consecutive years, supporting its appeal to income-focused investors despite weaker reported earnings. Johnson & Johnson’s Profit Fell 96% Year-Over-Year
• Positive Sentiment: MedTech momentum includes the U.S. launch of the Shockwave C2 Aero Fly coronary IVL catheter, designed to reduce treatment time and strengthen J&J’s cardiovascular-device franchise. TD Cowen reiterated a Buy rating with a $300 price target. Johnson & Johnson Launches Next-Generation Shockwave Catheter

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 64,515 shares of company stock valued at $17,271,766. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.7%

Shares of JNJ opened at $257.64 on Thursday. The company has a market cap of $620.90 billion, a PE ratio of 39.04, a P/E/G ratio of 2.56 and a beta of 0.21. The business has a fifty day moving average of $265.46 and a 200 day moving average of $249.94. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the firm earned $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.